Based on the multiplex assay results, GCF concentrations of MMP8 were downregulated in AD patients versus healthy controls, suggesting that MMP8 could be a suitable biomarker candidate for a future non-invasive diagnosis of moderate and severe AD. Here, MMP8 is linked to Alzheimer disease.